Application of KRAS Vaccine in the Treatment of KRAS-mutated Malignancies
ConditionMalignant Tumors
Trial statusRecruiting
Trial phasePhase 1
Trial typeInterventional
Biological sexAll
Age18+
SponsorSichuan University
About this trial
The goal of this study is to evaluate the safety and efficacy of mRNA vaccine for the KRAS mutation malignant tumors.
Eligibility criteria
Qualifiers
Male or female participants ≥18 years of age.
Participants with solid tumors confirmed to carry KRAS mutations.
At least one measurable lesion according to RECIST 1.1 criteria.
ECOG physical condition score: 0-1 point.
Disqualifiers
Patients with a history of other malignancies.
Presence of primary central nervous system (CNS) tumors, active CNS metastatic tumors, or carcinomatous meningitis, either historically or identified during screening.
Uncontrolled moderate to massive serous cavity effusion.
Confirmed presence of other classic gene variants.
Trial design
Treatments tested in this trial
- KRAS-mutated mRNA vaccine
- TORIPALIMAB
- Pemetrexed+carboplatin
Treatment groups
20 Participants
are divided into 2 treatment groupsSponsors and collaborators
Sichuan University
Lead sponsor
West China Hospital
Collaborator
Source ClinicalTrials.gov